Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management, ensuring safety and liquidity while aiming to enhance returns for the company and its shareholders [2][3][20]. Investment Overview - Investment Purpose: The objective is to improve the efficiency of raised funds, ensuring that the use of these funds does not affect project construction and safety, while increasing returns for the company and shareholders [3]. - Investment Amount: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][16]. - Source of Funds: The cash management funds will come from temporarily idle raised funds from the company's initial public offering in 2019 [5]. Fund Management - Fund Usage: The raised funds from the IPO amounted to RMB 1,588.29 million, with a net amount of RMB 1,529.27 million after deducting issuance costs. All funds have been deposited in a special account approved by the board [6][24]. - Investment Projects: The raised funds are allocated for international pharmaceutical R&D and working capital, with adjustments made to project timelines as necessary [7][23]. Investment Methodology - Investment Products: The company will invest in low-risk, liquid, and capital-protected products such as agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates, with a maximum term of 12 months [10][16]. - Implementation: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11]. Cash Management Returns - Return Allocation: Earnings from cash management will be prioritized to cover any shortfalls in project investment amounts and will be managed according to regulatory requirements [12]. Recent Cash Management Situation - Recent 12-Month Overview: The authorization for cash management is valid for 12 months, allowing for rolling use of funds within the specified limits [13][14]. Board Approval Process - Approval Details: The board approved the cash management proposal on November 7, 2025, confirming that it would not affect the normal operation of the company's investment plans [15][21]. Impact on Company - Operational Impact: The planned cash management will not affect the normal operations or project funding of the company, and it aims to generate additional investment returns [20][29].
上海昊海生物科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告